Clinical trials: Liraglutide
Type 2 Diabetes
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.
- Trial name
- AWARD-6 (NCT01624259)
- Testing
- LY2189265, Liraglutide, Metformin
- Where
- 57 sites in United States, Czechia and 8 more
- Volunteers
- 599 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India
This study is conducted in Asia. The aim of this study is to evaluate the safety and effectiveness of liraglutide in subjects with type 2 diabetes mellitus.
- Trial name
- Lead-In (NCT01212133)
- Testing
- liraglutide
- Where
- India
- Volunteers
- 1,386 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes…
- Trial name
- NCT00700817
- Testing
- liraglutide, sitagliptin, metformin
- Where
- 166 sites in United States, Canada and 13 more
- Volunteers
- 665 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentration of the administered…
- Trial name
- NCT00943501
- Testing
- liraglutide
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY®…
- Trial name
- NCT06559722
- Testing
- Insulin Degludec/liraglutide Injection, XULTOPHY®
- Volunteers
- 510 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ V (NCT01952145)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 91 sites in United States, Argentina and 8 more
- Volunteers
- 557 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A phase 2 study in two parts (A \& B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03555994
- Testing
- MEDI0382, Liraglutide
- Where
- 3 sites in Netherlands, Sweden and 1 more
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Diabetes, Healthy
Safety and Tolerability of NN9068 in Healthy Male Volunteers
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068.
- Trial name
- NCT00983021
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study.
- Trial name
- NCT03856047
- Testing
- NNC0174-0833, Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Knee Osteoarthritis
Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee
This phase I study is a multicenter, randomized, double-blind, placebo-controlled study to assess the safety and tolerability of single ascending dose of IA 4P-004 in participants, Between 18 and 80 years of age, with target knee…
- Trial name
- LASARE (NCT05419856)
- Testing
- 4P-004
- Where
- 3 sites in Belgium
- Volunteers
- 34 people
- Sponsor
- 4Moving Biotech
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed by HbA1c after 24 weeks and 52…
- Trial name
- NCT00395746
- Testing
- sulfonylurea, liraglutide
- Where
- Japan
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose…
- Trial name
- DUALTM IX (NCT02773368)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 88 sites in United States, Argentina and 9 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
This was a four-period crossover study to assess the glycemic effects of a single dose of oxyntomodulin (OXM) on the glucose levels in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01373450
- Testing
- Oxyntomodulin, Liraglutide 0.6 mg, Liraglutide 1.2 mg
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The trial is designed to compare the effect on glycaemic control of liraglutide or glimepiride added to metformin in subjects with type 2 diabetes
- Trial name
- NCT00614120
- Testing
- liraglutide, glimepiride, metformin
- Where
- 50 sites in China, India and 1 more
- Volunteers
- 929 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir
- Trial name
- NCT00873223
- Testing
- liraglutide, insulin detemir
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.
- Trial name
- NCT01558271
- Testing
- LY2189265, Liraglutide
- Where
- 14 sites in Japan
- Volunteers
- 492 people
- Sponsor
- Eli Lilly and Company